How much profit has WAVE Life Sciences made this year?
WAVE Life Sciences has made -149.02 M USD this year.
WAVE Life Sciences Net Income 2024
WAVE Life Sciences Net Income
-149.02 M USD
Ticker
WVE
ISIN
SG9999014716
WKN
A1436W
In 2024, WAVE Life Sciences's profit amounted to -149.02 M USD, a 159.1% increase from the -57.51 M USD profit recorded in the previous year.
The WAVE Life Sciences Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2029e | 147.64 |
| 2028e | 31.18 |
| 2027e | -27.94 |
| 2026e | -140.12 |
| 2025e | -144.11 |
| 2024e | -149.02 |
| 2023 | -57.51 |
| 2022 | -161.82 |
| 2021 | -122.25 |
| 2020 | -149.91 |
| 2019 | -193.64 |
| 2018 | -146.65 |
| 2017 | -101.98 |
| 2016 | -55.66 |
| 2015 | -19.2 |
| 2014 | -5.23 |
| 2013 | -3.32 |
WAVE Life Sciences Revenue, EBIT, Net Income SG9999014716 · A1436W
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into WAVE Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by WAVE Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects WAVE Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of WAVE Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into WAVE Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing WAVE Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on WAVE Life Sciences’s growth potential.
WAVE Life Sciences Revenue, EBIT and net profit per share
| Date | WAVE Life Sciences Revenue | WAVE Life Sciences EBIT | WAVE Life Sciences Net Income |
|---|---|---|---|
| 2029e | 519.25 M undefined | 0 undefined | 147.64 M undefined |
| 2028e | 323.49 M undefined | 30.95 M undefined | 31.18 M undefined |
| 2027e | 210.15 M undefined | -41.58 M undefined | -27.94 M undefined |
| 2026e | 97.42 M undefined | -156.08 M undefined | -140.12 M undefined |
| 2025e | 66.66 M undefined | -154.08 M undefined | -144.11 M undefined |
| 2024e | 70.53 M undefined | -147.36 M undefined | -149.02 M undefined |
| 2023 | 113.31 M undefined | -68 M undefined | -57.51 M undefined |
| 2022 | 3.65 M undefined | -162.72 M undefined | -161.82 M undefined |
| 2021 | 40.96 M undefined | -127.02 M undefined | -122.25 M undefined |
| 2020 | 20.08 M undefined | -153.38 M undefined | -149.91 M undefined |
| 2019 | 15.98 M undefined | -208.32 M undefined | -193.64 M undefined |
| 2018 | 14.41 M undefined | -159.52 M undefined | -146.65 M undefined |
| 2017 | 3.89 M undefined | -102.39 M undefined | -101.98 M undefined |
| 2016 | 1.09 M undefined | -55.72 M undefined | -55.66 M undefined |
| 2015 | 150,000 undefined | -19.3 M undefined | -19.2 M undefined |
| 2014 | 0 undefined | -5.39 M undefined | -5.23 M undefined |
| 2013 | 0 undefined | -3.57 M undefined | -3.32 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 0 USD | -3.57 M USD | -3.32 M USD |
| 2014 | 0 USD | -5.39 M USD | -5.23 M USD |
| 2015 | 150,000 USD | -19.3 M USD | -19.2 M USD |
| 2016 | 1.09 M USD | -55.72 M USD | -55.66 M USD |
| 2017 | 3.89 M USD | -102.39 M USD | -101.98 M USD |
| 2018 | 14.41 M USD | -159.52 M USD | -146.65 M USD |
| 2019 | 15.98 M USD | -208.32 M USD | -193.64 M USD |
| 2020 | 20.08 M USD | -153.38 M USD | -149.91 M USD |
| 2021 | 40.96 M USD | -127.02 M USD | -122.25 M USD |
| 2022 | 3.65 M USD | -162.72 M USD | -161.82 M USD |
| 2023 | 113.31 M USD | -68 M USD | -57.51 M USD |
| 2024e | 70.53 M USD | -147.36 M USD | -149.02 M USD |
| 2025e | 66.66 M USD | -154.08 M USD | -144.11 M USD |
| 2026e | 97.42 M USD | -156.08 M USD | -140.12 M USD |
| 2027e | 210.15 M USD | -41.58 M USD | -27.94 M USD |
| 2028e | 323.49 M USD | 30.95 M USD | 31.18 M USD |
| 2029e | 519.25 M USD | 0 USD | 147.64 M USD |
WAVE Life Sciences stock margins SG9999014716 · A1436W
The WAVE Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of WAVE Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for WAVE Life Sciences.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the WAVE Life Sciences's sales revenue. A higher gross margin percentage indicates that the WAVE Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the WAVE Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the WAVE Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the WAVE Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the WAVE Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the WAVE Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
WAVE Life Sciences Margin History
| WAVE Life Sciences Gross margin | WAVE Life Sciences Profit margin | WAVE Life Sciences EBIT margin | WAVE Life Sciences Profit margin |
|---|---|---|---|
| 2029e | 0 % | 0 % | 28.43 % |
| 2028e | 0 % | 9.57 % | 9.64 % |
| 2027e | 0 % | -19.79 % | -13.3 % |
| 2026e | 0 % | -160.23 % | -143.84 % |
| 2025e | 0 % | -231.13 % | -216.18 % |
| 2024e | 0 % | -208.93 % | -211.29 % |
| 2023 | 0 % | -60.01 % | -50.76 % |
| 2022 | 0 % | -4,458.08 % | -4,433.42 % |
| 2021 | 0 % | -310.11 % | -298.46 % |
| 2020 | 0 % | -763.84 % | -746.56 % |
| 2019 | 0 % | -1,303.63 % | -1,211.76 % |
| 2018 | 0 % | -1,107.01 % | -1,017.7 % |
| 2017 | 0 % | -2,632.13 % | -2,621.59 % |
| 2016 | 0 % | -5,111.93 % | -5,106.42 % |
| 2015 | 0 % | -12,866.67 % | -12,800 % |
| 2014 | 0 % | 0 % | 0 % |
| 2013 | 0 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 0 % | 0 % | 0 % |
| 2014 | 0 % | 0 % | 0 % |
| 2015 | 0 % | -12,866.67 % | -12,800 % |
| 2016 | 0 % | -5,111.93 % | -5,106.42 % |
| 2017 | 0 % | -2,632.13 % | -2,621.59 % |
| 2018 | 0 % | -1,107.01 % | -1,017.7 % |
| 2019 | 0 % | -1,303.63 % | -1,211.76 % |
| 2020 | 0 % | -763.84 % | -746.56 % |
| 2021 | 0 % | -310.11 % | -298.46 % |
| 2022 | 0 % | -4,458.08 % | -4,433.42 % |
| 2023 | 0 % | -60.01 % | -50.76 % |
| 2024e | 0 % | -208.93 % | -211.29 % |
| 2025e | 0 % | -231.13 % | -216.18 % |
| 2026e | 0 % | -160.23 % | -143.84 % |
| 2027e | 0 % | -19.79 % | -13.3 % |
| 2028e | 0 % | 9.57 % | 9.64 % |
| 2029e | 0 % | 0 % | 28.43 % |
WAVE Life Sciences Aktienanalyse
What does WAVE Life Sciences do?
WAVE Life Sciences Ltd is a biotechnology company dedicated to the development of nucleic acid preparations for the treatment of genetically inherited diseases. The company was founded in 2012 and is headquartered in Singapore. WAVE Life Sciences' business model is focused on developing specific nucleic acid sequences that can selectively silence or correct defective genes associated with various diseases. The company offers these sequences as therapeutics that enable personalized treatment for patients. The company utilizes a proprietary platform technology called "AVIENNA" to selectively silence or correct defective genes. "AVIENNA" aims to optimize the physical properties of nucleic acids to improve their effectiveness and duration of action. WAVE Life Sciences has three business areas: neurology, cardiovascular diseases, and metabolic diseases. In the neurology area, the company focuses on the development of therapeutics for the treatment of amyotrophic lateral sclerosis (ALS) and Huntington's disease. In the cardiovascular diseases area, the company is working on therapeutics for cardiovascular diseases such as heart attack, stroke, and atherosclerosis. In the metabolic diseases area, WAVE Life Sciences is focused on the development of therapeutics for rare metabolic diseases such as Crohn's disease and Pompe disease. The most well-known product in WAVE Life Sciences' pipeline is "WVE-120101", a therapeutic for the treatment of ALS. The drug has been developed to target mutations in the SOD1 gene that can lead to ALS. WVE-120101 is currently in clinical trials and has the potential to become the first approved medication for patients with ALS. WAVE Life Sciences also collaborates closely with other companies to exchange technologies and know-how. In 2018, the company entered into a strategic partnership with Takeda Pharmaceutical to jointly develop therapeutics for the treatment of gastrointestinal diseases. The partnership aims to leverage the strengths of both companies and accelerate the development of innovative therapeutics. Overall, WAVE Life Sciences has a promising portfolio of therapeutics that have the potential to improve the lives of patients with genetically inherited diseases. The company follows a systematic and scientifically-based strategy in drug development to ensure the effectiveness and safety of its products. With its innovative business model and dedicated research and development, WAVE Life Sciences is well positioned to achieve a leading position in the biotechnology industry in the future. WAVE Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding WAVE Life Sciences's Profit Margins
The profit margins of WAVE Life Sciences represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of WAVE Life Sciences's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating WAVE Life Sciences's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
WAVE Life Sciences's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When WAVE Life Sciences’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about WAVE Life Sciences stock
How has the profit developed compared to last year?
The profit has increased by 159.1% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does WAVE Life Sciences publish its earnings?
WAVE Life Sciences publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of WAVE Life Sciences?
The profits of WAVE Life Sciences are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of WAVE Life Sciences?
You can learn more about the earnings of WAVE Life Sciences by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does WAVE Life Sciences pay?
Over the past 12 months, WAVE Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, WAVE Life Sciences is expected to pay a dividend of 0 USD.
What is the dividend yield of WAVE Life Sciences?
The current dividend yield of WAVE Life Sciences is .
When does WAVE Life Sciences pay dividends?
WAVE Life Sciences pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of WAVE Life Sciences?
WAVE Life Sciences paid dividends every year for the past 0 years.
What is the dividend of WAVE Life Sciences?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is WAVE Life Sciences located?
WAVE Life Sciences is assigned to the 'Health' sector.
Wann musste ich die Aktien von WAVE Life Sciences kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of WAVE Life Sciences from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.
When did WAVE Life Sciences pay the last dividend?
The last dividend was paid out on 11/5/2024.
What was the dividend of WAVE Life Sciences in the year 2023?
In the year 2023, WAVE Life Sciences distributed 0 USD as dividends.
In which currency does WAVE Life Sciences pay out the dividend?
The dividends of WAVE Life Sciences are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von WAVE Life Sciences
Our stock analysis for WAVE Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of WAVE Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- WAVE Life Sciences Revenue
- WAVE Life Sciences Net Income
- WAVE Life Sciences P/E
- WAVE Life Sciences P/S
- WAVE Life Sciences EBIT
- WAVE Life Sciences Dividend
- WAVE Life Sciences Stocks
- WAVE Life Sciences Market capitalization
- WAVE Life Sciences Debt
- WAVE Life Sciences Liabilities
- WAVE Life Sciences Equity
- WAVE Life Sciences AAQS
- WAVE Life Sciences Employees
- WAVE Life Sciences ROE
- WAVE Life Sciences ROA
- WAVE Life Sciences ROCE
